Acute Myeloid Leukemia is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally.​ -With relapse rates as high as 50%, routine measurable residual disease (MRD) ...

High-dose daunorubicin improved complete response rates in patients aged 60 and younger and survival in those younger than 50. Despite considerable advances during the past 20 years in the diagnostic ...

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...

Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study We performed a population-based ...

TORONTO, June 16, 2025 /CNW/ - Daiichi Sankyo's (TSE: 4568) VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline induction and ...

FDA fails to approve Clolar in elderly adults with AML Agency says Genzyme needs to conduct additional trial Result was expected; Genzyme's shares up 1.7 percent BOSTON, Oct 6 (Reuters) - Genzyme Corp ...

Leukemia in older adults causes symptoms like weight loss, fatigue, and night sweats. Your outlook depends on the type of leukemia you have. Leukemia is a type of cancer that affects the blood cells, ...

Soheil Meshinchi, MD, PhD, a world leader in developing novel approaches to treating acute myeloid leukemia (AML), has been ...